ATS 2020 Advance Program

Objectives At the conclusion of this session, the participant will be able to: • learn the newest datasets of LungMAP that could inform lung research; • gain understanding of the innovative technologies for molecular profiling, imaging, and data analysis of the developing lung; • learn how to access and use the LungMAP resources. Molecular Atlas of Lung Development (LungMAP) is an NHLBI-sponsored program. The overall goal of this program is to build an open-access reference resource by creating a comprehensive molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Speakers will demonstrate how systems biology and bioinformatic approaches can be used to inform processes in development that are recapitulated in disease and repair. The session will also illustrate the LungMAP data pipeline which integrates high resolution multi-omics and imaging data. Chairing: S. Lin, PhD, Bethesda, MD J.A. Whitsett, MD, Cincinnati, OH 11:45 Building a Multidimensional Map of Developing Human Lung J.A. Whitsett, MD, Cincinnati, OH 11:55 Multi-Modal Characterization of Three Human Lung Niches at the Single Cell Level E.E. Morrisey, PhD, Philadelphia, PA 12:05 Spatiotemporal Lung Imaging and Omics C. Ansong, PhD, Richland, WA 12:15 Decoding the Cellular Niches Critical for Lung Maturation and Pathogenesis X. Sun, PhD, San Diego, CA 12:25 LungMAP 2 DCC P. White, PhD, Cincinnati, OH 12:35 Biorepository for Investigation of Diseases of the Lung (BRINDL): Phase II G.S. Pryhuber, MD, Rochester, NY DIVISION OF LUNG DISEASES/NHLBI L27 CAPTURE: A NEW APPROACH FOR IDENTIFYING PATIENTS WITH UNDIAGNOSED COPD 11:45 a.m. - 12:45 p.m. Target Audience All levels of health care providers, patients and their caregivers, payors, pharma industry operating in the space of COPD, Objectives At the conclusion of this session, the participant will be able to: • learn new strategies to identify those with undiagnosed COPD by understanding what CAPTURE; • understand the issues related to COPD underdiagnosis; • evaluate the possible implications of the study for public health benefit. The session will explain what an innovative approach to COPDCase Finding, CAPTURE. The discussion will describe the development of the tool and how it is envisioned to be used and why the development of this tool has relevance for the COPD community at large. The speakers will illustrate in detail the aims of an ongoing validation cluster randomized trial, the methodology used, and the progress made at the time of the conference. A dedicate time for Q&A at the end of the session will address the audience’s question. Chairing: A. Punturieri, MD, PhD, Bethesda, MD B.J. Make, MD, Denver, CO 11:45 Introduction to the CAPTURE study F.J. Martinez, MD, MS, New York, NY 11:57 PBRNs and CAPTURE B.P. Yawn, MD, MSc, MPH, Miami, FL 12:09 Aim 1 and 3 of the CAPTURE Study M.K. Han, MD, MS, Ann Arbor, MI 12:21 Aim 2 of the CAPTURE Study R.W. Brown, MD, MPH, AE-C, Ann Arbor, MI 12:33 Questions and Answers A. Punturieri, MD, PhD, Bethesda, MD ATS 2020 • Philadelphia, PA 138 WEDNESDAY • MAY 20